Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • GEMO Study Collaborators - (Autor:in)
  • Karin Kast - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe (Autor:in)
  • Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
  • FIRC Institute of Molecular Oncology
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • Roswell Park Cancer Institute
  • Universität zu Köln
  • Université Laval
  • Institute of Cancer Research
  • University of Cambridge
  • Netherlands Cancer Institute
  • Queensland Institute of Medical Research
  • University of Otago
  • University of Algarve
  • IRCCS Istituto Oncologico Veneto - Padova
  • Pomeranian Medical University in Szczecin
  • Akademisches Krankenhaus Maastricht (UMC+)
  • The University of Chicago
  • University of California at San Francisco
  • University of Pennsylvania
  • University of Texas at Austin
  • Cedars-Sinai Medical Center
  • Columbia University
  • Case Western Reserve University
  • University of Melbourne
  • University of Utah
  • Vilnius University
  • University of Pretoria
  • University of Antwerp
  • Universität Kopenhagen
  • CIBER - Centro de Investigación Biomédica en Red
  • Instituto de Salud Carlos III
  • Hospital de Cruces
  • Deutsches Krebsforschungszentrum (DKFZ)

Abstract

Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants inmany candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysiswas performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies.

Details

OriginalspracheEnglisch
Seiten (von - bis)308-316
Seitenumfang9
FachzeitschriftCancer Epidemiology Biomarkers and Prevention
Jahrgang24
Ausgabenummer1
PublikationsstatusVeröffentlicht - 1 Jan. 2015
Peer-Review-StatusJa

Externe IDs

researchoutputwizard legacy.publication#66091
Scopus 84921028142
PubMed 25336561

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete